Background: Dual contraceptive is the use of a barrier like condom along with any modern contraceptive methods which has double significance for the prevention STI including HIV and unintended pregnancy. The prevalence and determinants of dual contraceptive utilization described by different studies were highly inconsistent in Ethiopia. Therefore, this systematic review and meta-analysis aimed to estimate the pooled prevalence and determinants of dual contraceptive utilization among HIV positive women in Ethiopia.
Methods: International database mainly Pub Med, Google scholar, HINARI, EMBASE, Cochrane Library, AJOL was applied to identify original studies. STATA software version 14 was applied to analyze the pooled prevalence of dual contraceptive. I test statistics was computed to check the presence of heterogeneity across the studies and eggers test was used to identify publication bias. The pooled prevalence of dual contraceptive utilization was estimated by using a random effects model. The associations between determinants and dual contraceptive utilization were evaluated by using both random and fixed effect models.
Result: A total 9 studies with 9168 HIV positive women were enrolled in this study. The pooled prevalence of dual contraceptive utilization among HIV positive women in Ethiopia was 26.14% (95% CI 21.20-31.08). Disclosure of HIV status (OR = 4.18,95%CI:2.26-7.72), partner involvement in post-test counselling (OR = 2.31,95%CI:1.63-3.25), open discussion about dual contraceptive with partner (OR = 4.27 95% CI:1.69-10.77), provision of counselling on dual contraceptives by health care provider (OR = 4.47,95% CI:3.81-5.24) and CD4 count > 350 cells/ mm (OR = 3.87,95%CI:3.53-4.23) were among the significant factors associated with dual contraceptive utilization.
Conclusion: The overall prevalence of dual contraceptive utilization among HIV positive women was significantly low. Disclosure of HIV status, partner involvement in post-test counselling, open discussion about dual contraceptive with partner, counselling on dual contraceptive by health care provider and CD4 count > 350 cells/ mm were positively affect dual contraceptive utilization. This study implies the need to develop plans and policies to improve partner involvement posttest counseling, integrate the counseling and provision of dual contraceptive at ART clinic at each level of health system.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247245 | PMC |
| http://dx.doi.org/10.1186/s40834-021-00161-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Injectable depot medroxyprogesterone acetate (DMPA) is the most common contraceptive choice among young women in Uganda, where HIV burden is high and HIV pre-exposure prophylaxis (PrEP) may be offered. For young women who choose to use both agents concurrently, it is unknown whether they will experience declines in BMD beyond those elicited by either product singly.
Methods: From 2018-2022, we conducted a 2-year prospective study with women ages 16-25 years in Kampala, Uganda desiring pregnancy and HIV prevention.
Evaluation of dimethandrolone undecanoate in non-human primates as a candidate for long-acting injectable male contraceptive.
Andrology
December 2024
Contraceptive Development Program, Division of Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Health, Bethesda, Maryland, USA.
Background: Dimethandrolone undecanoate (DMAU) is under development as a single agent hormonal male contraceptive. DMAU is a prodrug hydrolyzed by esterase(s) to the active metabolite dimethandrolone (DMA) which has dual androgenic and progestogenic actions. Phase 1 clinical trial results show DMAU to be well-tolerated as an oral contraceptive in healthy men; however, delivery of DMAU as a long-acting injectable rather than a daily oral formulation would provide user compliance benefits and address oral bioavailability concerns.
View Article and Find Full Text PDFCost-effectiveness of linking HIV and family planning services to prevent unintended pregnancies among women living with HIV.
PLoS One
December 2024
Department of Operational and Implementation Research, ICMR- National Institute for Research in Reproductive and Child Health- HTA Regional Resource Hub, Mumbai, Maharashtra, India.
Article Synopsis
- * A model was used to analyze costs and health outcomes, showing that strengthening these linked services can significantly diminish unintended pregnancies, induced abortions, live births, and infant infections.
- * Results indicate that for a relatively low cost, this integrated approach can avert multiple negative outcomes, supporting the idea that enhancing healthcare provider training and contraception methods is a cost-effective solution.
Semisynthetic p-Coumaric Acid Derivatives as Lead Dual Inhibitors Against DPP-IV and GSK-3β for Antidiabetic Therapy.
Chem Biol Drug Des
November 2024
Programa de Pós-Graduação Em Química, Universidade Federal Do Espírito Santo, Vitória, ES, Brazil.
Article Synopsis
- Type 2 diabetes mellitus is becoming a major global health issue, expected to nearly double in prevalence from 194 million in 2003 to 333 million by 2025, with 90%-95% of cases being type 2.
- New research focuses on developing dual inhibitors for type 2 diabetes through synthesizing ester and triazole derivatives of p-coumaric acid, using methods like Williamson synthesis and Microwave-assisted click reaction.
- These synthesized compounds were tested and showed effective inhibition against two key enzymes, GSK-3β kinase and DPP-IV, indicating that p-coumaric acid derivatives are promising candidates for new diabetes treatments.
Polycystic ovary syndrome and type 1 diabetes - the current state of knowledge.
Endokrynol Pol
October 2024
Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Medical University of Silesia, Katowice, Poland.
Article Synopsis
- Type 1 diabetes mellitus (T1DM) and polycystic ovary syndrome (PCOS) are interconnected conditions that can worsen metabolic health and raise cardiovascular risks, significantly impacting patients' quality of life.
- Recommended treatment includes lifestyle changes like increased physical activity and weight loss, alongside pharmacological options such as metformin and GLP-1 receptor agonists.
- Emerging treatments and supplements, such as anti-androgens and dietary components, plus the gut microbiome's role, are areas of interest for improving symptoms and metabolic control in patients with both T1DM and PCOS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!